Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 16/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 15/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 13/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.43 |
| ▸ | PTGFR | P43088 | 3/20 | 0.42 |
| ▸ | PTGIR | P43119 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603138 | 1.00 | BACE1 (0.51) | BACE1PTGER3PTGER2PTGER4TBXAS1 | |
| SCHEMBL305026 | 0.87 | BACE1 (0.47) | BACE1TBXAS1CA1CA2HTT | |
| SCHEMBL28566740 | 0.84 | BACE1 (0.69) | BACE1PTGER3PTGER2PTGER4TBXAS1 | |
| SCHEMBL875044 | 0.82 | BACE1 (0.39) | BACE1HTT | |
| SCHEMBL4616887 | 0.80 | PPARG (0.45) | BACE1TBXAS1CA1CA2CA4 | |
| SCHEMBL4603142 | 0.80 | PPARG (0.45) | BACE1TBXAS1CA1CA2CA4 | |
| SCHEMBL305028 | 0.79 | BACE1 (0.39) | BACE1TBXAS1 | |
| SCHEMBL1564661 | 0.77 | HTT (0.44) | HTT | |
| SCHEMBL8573281 | 0.76 | PTGER3 (0.57) | PTGER3PTGER2PTGER4TBXAS1PTGDR | |
| SCHEMBL2331057 | 0.75 | AKT1 (0.40) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | BACE1 59/4885PTGER3 4646/4885PTGER2 3679/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | BACE1 77/4885PTGER3 4693/4885PTGER2 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.